These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26452602)

  • 1. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer.
    Marina O; Warner J; Ye H; Grills IS; Shah C; Wallace M; Gustafson GS; Brabbins DS; Martinez AA; Krauss DJ
    Brachytherapy; 2014; 13(2):163-8. PubMed ID: 24295963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
    Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
    Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
    Raleigh DR; Chang AJ; Tomlin B; Cunha JA; Braunstein SE; Shinohara K; Gottschalk AR; Roach M; Hsu IC
    Brachytherapy; 2015; 14(6):795-800. PubMed ID: 26198421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.
    Press RH; Morgan TM; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel P; Jani AB; Rossi PJ
    Brachytherapy; 2019; 18(1):13-21. PubMed ID: 30262410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
    Crook J; Moideen N; Arbour G; Castro F; Araujo C; Batchelar D; Halperin R; Hilts M; Kim D; Petrik D; Rose J; Cheng JC; Bachand F
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):59-68. PubMed ID: 38493901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
    Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
    BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.
    Contreras JA; Wilder RB; Mellon EA; Strom TJ; Fernandez DC; Biagioli MC
    Int Braz J Urol; 2015; 41(1):40-5. PubMed ID: 25928509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.
    Zelefsky MJ; Poon BY; Eastham J; Vickers A; Pei X; Scardino PT
    Radiother Oncol; 2016 Jan; 118(1):85-91. PubMed ID: 26780999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
    Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
    Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
    Morton G; Chung HT; McGuffin M; Helou J; D'Alimonte L; Ravi A; Cheung P; Szumacher E; Liu S; Al-Hanaqta M; Zhang L; Mamedov A; Loblaw A
    Radiother Oncol; 2017 Jan; 122(1):87-92. PubMed ID: 27823821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
    Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
    Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.